Perrigo Company PRGO Upper Respiratory — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Perrigo Company in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Perrigo Company’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Perrigo Company's upper respiratory — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Perrigo Company's upper respiratory — net sales?
- Perrigo Company (PRGO) reported upper respiratory — net sales of $197.4M in Q1 2026.
- How has Perrigo Company's upper respiratory — net sales changed year-over-year?
- Perrigo Company's upper respiratory — net sales decreased by 8.1% year-over-year, from $214.7M to $197.4M.
- What is the long-term trend for Perrigo Company's upper respiratory — net sales?
- Over 4 years (2021 to 2025), Perrigo Company's upper respiratory — net sales has grown at a 4.0% compound annual growth rate (CAGR), from $702.7M to $821M.
- What does upper respiratory — net sales mean?
- This metric represents the total revenue generated from the sale of products within the upper respiratory category, which typically includes over-the-counter medications for cold, cough, allergy, and sinus relief. It serves as a key indicator of the segment's market demand and competitive performance within the consumer healthcare landscape. Tracking these sales helps investors assess the company's ability to capture market share in seasonal health categories and manage product portfolio growth.